Prelude Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $3,424 | $0 |
Gross Profit | -452 | -426 | 3,093 | -279 |
EBITDA | -36,712 | -34,343 | -37,048 | -33,385 |
EBIT | -37,164 | -34,769 | -37,379 | -33,664 |
Net Income | -34,740 | -31,431 | -33,075 | -30,608 |
Net Change In Cash | 0 | 0 | 3,424 | 0 |
Free Cash Flow | -23,416 | -32,080 | -24,707 | -26,274 |
Cash | 27,828 | 24,707 | 25,291 | 15,896 |
Basic Shares | 75,762 | 75,735 | 69,591 | 67,639 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1,169 | -3,042 | -2,243 | -542 |
EBITDA | -131,108 | -122,216 | -112,820 | -58,221 |
EBIT | -132,277 | -123,540 | -113,735 | -58,763 |
Net Income | -121,832 | -107,336 | -110,779 | -56,929 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -110,576 | -86,748 | -85,854 | -46,798 |
Cash | 25,291 | 30,605 | 31,828 | 218,309 |
Basic Shares | 60,357 | 47,371 | 47,602 | 43,705 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.46 |
2024-03-31 | -$0.42 |
2023-12-31 | -$0.46 |
2023-09-30 | -$0.45 |
